February 2, 2015 -- Mylan Inc. today announced that it has, through its Indian subsidiary Mylan Laboratories Limited, signed a definitive agreement to acquire certain female health care businesses from Famy Care Limited, a specialty women's health care company with global leadership in generic oral contraceptive products (OCPs) for $750 million in cash plus additional contingent payments of up to $50 million. Cravath, Swaine & Moore LLP represented Mylan in connection with this transaction, which is expected to close in the second half of 2015, subject to regulatory approvals and certain closing conditions.

The Cravath team was led by partners Mark I. Greene and Minh Van Ngo and included associates Kyle C. Harmon and Zara Bari (M&A); associates Kara L. Mungovan and Stephen R. Severo (tax); associates Jonathan J. Katz and Matthew J. Bobby (executive compensation and benefits); partner Matthew Morreale (environmental) and partner David J. Kappos (intellectual property). Christopher P. Davis also worked on intellectual property matters.